Value & Access Strategy for biotech and medtech
Unlock
the value of science
Build bridges between science and revenue thanks to Value & Access Strategy.
Great science needs the right strategy to succeed.
At Pharmaxess Consulting, I help biotech companies, investors and healthcare stakeholders structure and optimise the value of their projects through a unique Value & Access strategy.
My goal? To unlock the value of science and turn it into market opportunities and real-world impact.
What I do
Aligning development, value and clinical reality
01
Development strategy
- Structure R&D strategies (regulatory, nonclinical, clinical)
- Turn scientific and regulatory inputs into clear development plans
- Support project structuring (planning, milestones, coordination)
02
Value & access
- Define project value (unmet need, positioning, TPP)
- Analyse the competitive landscape
- Bring patient, payer and clinician perspectives in early
03
Decisions & narratives
- Turn scientific data into actionable decisions
- Identify key risks and strategic choices early
- Build clear, credible stories for partners and investors
Flagship offer
Evaluate your project the way investors and partners will.
An independent, multidisciplinary review of your development strategy, built on the Pharmaxess 5P framework. Relevant at every stage, from discovery to late development.
Clémentine Laurent, PhD
Value & Access Strategy Consultant
Who I am
Both sides of the equation
10+ years in biotech development and 5+ years in value and market access strategy, across drugs, medical devices and combination products.